Publications by authors named "Daniela Scattolin"

Claim this Profile
C
Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma.
Evgeniya Sharova, Paola Del Bianco, Loredana Urso, Micol Silic-Benussi, Daniela Scattolin

Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical insight on the pathway of SLFN11 as emergent biomarker in SCLC.
Daniela Scattolin, Frank W J Heijboer, Jules L Derks, Jan H von der Thüsen, Daphne W Dumoulin

Crit Rev Oncol Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.
Maria Lucia Reale, Daniela Scattolin, Antonio Vitale, Francesco Passiglia, Salvatore Grisanti

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort.
Daniela Scattolin, Anne-Marie C Dingemans, Alessandro Dal Maso, Valentina Guarneri, Joachim G J V Aerts

Eur J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257).
Giulia Pasello, Giulia Pigato, Daniela Scattolin, Stefania Lando, Sara Potente

J Exp Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Giulia Pasello, Martina Lorenzi, Daniela Scattolin, Alessandro Del Conte, Fabiana Cecere

Oncologist· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
Daniela Scattolin, Alessandro Dal Maso, Alessandra Ferro, Stefano Frega, Laura Bonanno

Cancer Treat Rev· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers.
Michela Verzè, Andrea Boscolo Bragadin, Roberta Minari, Giulia Pasello, Fabiana Perrone, Daniela Scattolin

J Liq Biopsy· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in fusion-positive non-small cell lung cancer: a case report.
Daniela Scattolin, Elena Scagliori, Antonio Scapinello, Alberto Fantin, Valentina Guarneri

Front Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective.
Giulia Pasello, Daniela Scattolin, Laura Bonanno, Francesca Caumo, Andrea Dell'Amore

Cancer Treat Rev· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte

Oncologist· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
Alessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, Sara Pilotto, Fabiana Cecere, Daniela Scattolin

Future Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Alessandro Dal Maso, Martina Lorenzi, Elisa Roca, Sara Pilotto, Marianna Macerelli, Daniela Scattolin

Clin Lung Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis